belantamab mafodotin
gsk
['dreamm,9', 'mmsm', 'belantamab,mafodotin', 'dreamm', 'belantamab', 'marker ']
congress l #ash22 daniel lowther describes detectable bcma levels in 98%/98.9% of patients in dreamm-1/dreamm-2 at progression. no evidence suggests bcma expression is completely lost after treatment with belantamab mafodotin, or total lymphocyte count negatively affected #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma